Last reviewed · How we verify
Genotypic resistance guided therapy
At a glance
| Generic name | Genotypic resistance guided therapy |
|---|---|
| Also known as | selection of antibiotic according to genotypic resistance |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization (NA)
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients (PHASE4)
- Early Targeted Antibiotic Therapy in Patients With Sepsis (NA)
- Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (PHASE4)
- Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment (PHASE4)
- Inflammation and Co-Infections in D²EFT (PHASE4)
- Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: